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ABSTRACT Shiga toxin (Stx)-producing Escherichia coli (STEC) is the main cause of
postdiarrheal hemolytic-uremic syndrome (HUS), a life-threatening clinical complica-
tion characterized by hemolytic anemia, thrombocytopenia, and acute renal failure
that mainly affects children. A relevant feature of STEC strains is the production of
Stx, and all of them express Stx1 and/or Stx2 regardless of the strain serotype.
Therefore, Stx detection assays are considered the most suitable methods for the
early detection of STEC infections. Single-domain antibodies from camelids (VHHs)
exhibit several advantages in comparison with conventional antibodies, making
them promising tools for diagnosis. In this work, we have exploited VHH technology
for the development of an immunocapture assay for Stx2 detection. Thirteen anti-
Stx2 VHHs previously obtained from a variable-domain repertoire library were se-
lected and evaluated in 130 capture-detection pair combinations for Stx detection.
Based on this analysis, two VHHs were selected and a double VHH-based biotin-
streptavidin capture enzyme-linked immunosorbent assay (ELISA) with spectrophoto-
metric detection was developed and optimized for Stx2 detection. This assay
showed an excellent analytical and clinical sensitivity in both STEC culture superna-
tants and stool samples even higher than the sensitivity of a commercial ELISA. Fur-
thermore, based on the analysis of stool samples, the VHH-based ELISA showed high
correlation with stx2 detection by PCR and a commercial rapid membrane-based im-
munoassay. The intrinsic properties of VHHs (high target affinity and specificity, sta-
bility, and ease of expression at high yields in recombinant bacteria) and their opti-
mal performance for Stx detection make them attractive tools for the diagnosis of
HUS related to STEC (STEC-HUS).
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Shiga toxin (Stx)-producing Escherichia coli (STEC) is an important foodborne patho-gen that can produce sporadic cases and outbreaks of gastroenteritis with diarrhea,
bloody diarrhea (BD), and hemolytic-uremic syndrome (HUS). HUS is a life-threatening
clinical condition characterized by microangiopathic hemolytic anemia, thrombocyto-
penia, and acute renal failure (1, 2). It is estimated that STEC causes annually more than
2.5 million cases of acute illness worldwide, among which several thousand trigger HUS
and hundreds of cases suffer severe kidney damage, often irreversible, or even death
(3). HUS related to STEC (STEC-HUS) is the leading cause of acute renal failure in
children worldwide; over 90% of HUS cases are associated with STEC infection in this
population (4). The incidence of STEC-HUS varies according to the country, and
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Argentina shows the highest HUS incidence worldwide, with almost 10 cases a year per
100,000 children under 5 years old. In this country, HUS shows an endemic behavior
and constitutes an important public health issue with high morbidity and mortality
rates (5).
STEC strains are characterized by the production of Shiga toxins (Stx[s]), which
constitute the main virulence factors in the pathogenesis of BD and HUS since they
spread to the target organs such as kidneys, resulting in cell receptor-mediated
internalization and toxicity (6, 7). Stx family members have an AB5 molecular configu-
ration in which an enzymatically active A subunit is noncovalently linked to five B
subunits. The A subunit inhibits protein synthesis in the target cells, and the B
pentamer binds the cellular receptor, globotriaosylceramide (Gb3), found primarily on
endothelial cells (8, 9). The STEC strains can produce two types of Stx(s), type 1 (Stx1)
and type 2 (Stx2), as well as their variants. For Stx1, three variants (a, c, and d) were
identified, among which Stx1a is the most prevalent. Stx1c is rare and does not cause
serious complications in humans, and Stx1d has not been detected in strains isolated
from humans. Within the Stx2 variants (a, b, c, d, e, f, and g), Stx2a is the most frequently
found in stool samples and the Stx2 subtype with the highest clinical and epidemio-
logical relevance. In STEC infections, severe disease is more often associated with STEC
strains that produce Stx2a rather than Stx1a (10, 11).
The diagnosis of STEC infections is based on the isolation and characterization of
STEC strains as well as free fecal Shiga toxin (FFStx) and/or stx gene detection. E. coli
O157:H7 is the dominant STEC serotype associated with sporadic cases and outbreaks
of BD and HUS in different parts of the world (2); however, a subset of non-O157:H7
STEC serotypes (O26:H11, O103:H2, O111:NM, O121:H19, O145:NM, and O45:H2, among
others) can cause a similar disease (5, 12). We have recently demonstrated that
serological diagnosis using serogroup-specific antigens for the most prevalent STEC
serogroups is a valuable and sensitive method for diagnosing STEC infections in
combination with bacteriological culture and Stx detection (13, 14). Irrespective of the
strain serotype, the common virulence trait of all STEC strains is the ability to produce
one or both Shiga toxins (Stx1 or Stx2). Therefore, Stx detection assays are considered
the most suitable methods for the timely and accurate diagnosis of STEC infections. The
gold standard test for free fecal Shiga toxin (FFStx) detection is the Vero cell cytotoxicity
assay because of its picogram-level analytical sensitivity (15). In addition, a number of
immunoassays for FFstx detection, such as enzyme-linked immunosorbent assays
(ELISAs) (16–18), membrane-based immunoassays (19–21), and immunochromato-
graphic systems (21–23), are available. All these tests use a combination of polyclonal
and/or monoclonal antibodies against the A or B subunits of the toxins. STEC infection
can also be confirmed by PCR assays targeting stx1 and/or stx2 genes that can be tested
on direct fecal samples, the culture medium after enrichment of the stool samples, or
samples obtained from the confluent growth zone in agar plates or from the isolated
strains (24, 25). However, stx gene(s) detection does not always correlate with disease
or expression of the toxin/s.
In addition to conventional heterotetrameric antibodies, camelids also produce
unusual homodimeric antibodies that are composed only of heavy chains known as
HCAbs for heavy-chain-only antibodies (26). The antigen-binding site of HCAbs consists
of one single variable domain, and the product of its recombinant expression is called
VH domain of heavy-chain antibodies (VHH) or nanobody (Ablynx). VHHs provide many
advantages over conventional polyclonal and monoclonal antibodies and currently
used antibody-based fragments (27). They can be easily engineered, cloned, and
expressed with high yields in a variety of expression systems, including E. coli. VHHs are
highly soluble and stable, even under denaturing conditions or at high temperatures,
and can be efficiently functionalized. Moreover, due to their small size they can
recognize unusual antigenic sites and penetrate tissues deeply. Therefore, VHHs are
very valuable immunoreagents that have been extensively used in diagnostics (28–32)
and therapy (33–36).
In this work, we have developed a double-VHH sandwich enzyme-linked immu-
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nosorbent assay (ELISA) for Stx2 detection. This VHH-based ELISA uses two different
VHHs for capture and detection and allows a sensitive and specific detection of Stx2a
in both STEC culture supernatants and stool samples. We propose that this unique,
tailor-made assay could be of great value for the diagnosis of STEC infections.
MATERIALS AND METHODS
Plasmids, bacterial strains, and growth conditions. The bacterial strains and plasmids used in this
work are listed in Table 1. The E. coli TOP10 strain (Invitrogen Life Technologies) was used for cloning
procedures and was grown on Luria-Bertani medium (LB; 10 g/liter tryptone, 5 g/liter yeast extract, and
10 g/liter NaCl) at 37°C. Tetracycline at 20 g/ml, chloramphenicol at 20 g/ml, kanamycin at 50 g/ml,
or ampicillin at 100 g/ml was added as needed to the medium.
Expression and purification of BLS-Stx2B. BLS-Stx2B was produced and purified as previously
described (37). In this chimera, Stx2a B subunit is covalently linked to the enzyme lumazine synthase from
Brucella spp. (BLS).
Cloning, expression, and purification of GST-Stx2B. The fusion of Stx2a B subunit to glutathione
S-transferase (GST-Stx2B) was generated using Gateway technology (38). Briefly, the gene that encodes
Stx2a B subunit (Gen Bank accession no. AAG55588.1) was amplified by PCR with the oligonucleotides
attB1-Stx2B-Fw (GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCGGCGGATTGTGCTAAA) and attB2-
Stx2B-Rv (GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGTCATTATTAAACTGCAC) (underlining indicates
the sequence of the attB1 or attB2 site) using Platinum Pfx DNA polymerase (Invitrogen Life Technolo-
gies) and genomic DNA from the EDL933 E. coli O157:H7 strain as the template. The amplification
product was cloned into the pDONR221 plasmid using the BP Clonase to generate the entry clone
pDONR221-Stx2B. The entry clone was recombined with the pDEST15 plasmid to generate the pDEST15-
Stx2B using the LR Clonase. For expression of GST-Stx2B, the E. coli BL21-CodonPlus (DE3)-RP strain was
transformed with the pDEST15-Stx2B plasmid. The resulting strain was grown overnight at 37°C with
agitation in LB medium supplemented with 20 g/ml chloramphenicol and 100 g/ml ampicillin and
reinoculated at 1:100 dilution into fresh LB. After incubation for 3 h at 37°C (optical density at 600 nm
[OD600] of 0.5), protein expression was induced by addition of isopropyl--D thiogalactopyranoside
(IPTG) to a final concentration of 1 mM. Following a 3-h induction period, the cells were harvested by
centrifugation, and the cytoplasmic extracts were obtained by lysis of the cells with lysis buffer (50 mM
Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% Triton X-100, 0.5 mg/ml lysozyme, 10 mM MgCl2, 2 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 2 mM EDTA, and 10 mg/ml DNase) and sonication. After centrifugation, the
soluble fraction was subjected to glutathione-Sepharose affinity chromatography according to the
manufacturer’s instructions (GE Healthcare Life Sciences).
Production of bacterial culture supernatants enriched in Stx1 and/or Stx2. Culture supernatants
of the STEC strains, which were used as a source of native Shiga toxins, were prepared according to the
protocol described by Karmali et al. with minor modifications (39). Isolated colonies (approximately 10
to 15 colonies) of the corresponding strain (Table 1) were resuspended in 100 l of tryptic soy broth
medium (TSB; 17 g/liter tryptone, 3 g/liter peptic digest of soybean, 2.5 g/liter glucose, 5 g/liter NaCl, and
5 g/liter K2PO4) and inoculated in 5 ml of TSB medium. After 24 h of incubation at 37°C under static
TABLE 1 Plasmids and strains used in this work
Plasmid or strain Description/characteristicsa Reference or source
Plasmids
pHEN4 Phagemid vector for phage display; HA tag, Ampr 47
pHEN6 Phagemid vector for phage display; 6His tag, Ampr 48
pDONR221 Entry vector for Gateway cloning system, Kanr Invitrogen
pDEST15 Expression vector for Gateway cloning system, Ampr Invitrogen
pDEST15-Stx2B pDEST15 containing the B subunit from Stx2a fused to GST, Ampr This work
E. coli strains
TOP10 F mcrA Δ(mrr-hsdRMS-mcrBC) 80dlacZΔM15 ΔlacX74 endA1 recA1 Δ(ara, leu)7697
araD139 galU galK nupG rpsL  (Strr)
Invitrogen
BL21-CodonPlus (DE3)-RP E. coli B F ompT hsdS(rB mB) dcm Tetr gal (DE3) endA Hte [argU proL Chlr] Stratagene
WK6 F= lacIq Δ(lacZ) M15 proA B Δ(lac-proAB) galE rpsL 48
O157:H7 (EDL933) Reference STEC strain, eae/ehx stx1/2 O157:H7 ANLIS-Malbrán (49)
O145:NM (FP 02/02) STEC isolation strain, eae/ehx stx2 O145:NM ANLIS-Malbrán
O145:NM (FP 1091/10) Non-STEC isolation strain, eae negative/ehx negative stx negative O145:NM ANLIS-Malbrán
(FP 817/12) STEC isolation strain, eae=/ehx stx1a O26:H11 ANLIS-Malbrán
(FP 447/11) STEC isolation strain, eae negative/ehx stx1c ONT:NM ANLIS-Malbrán
(FP 379/10) STEC isolation strain, eae negative/ehx negative stx2bO118 ONT:HNT ANLIS-Malbrán
(FP 550/12) STEC isolation strain, eae/ehx stx2cvh-a O157:H7 ANLIS-Malbrán
(FP 862/10) STEC isolation strain, eae negative/ehx negative stx2cvh-b ONT:H21 ANLIS-Malbrán
(FP 713/09) STEC isolation strain, eae negative/ehx stx2d O91:H21 ANLIS-Malbrán
(GG7) STEC isolation strain, eae/ehx negative stx2d O145:H34 ANLIS-Malbrán
aAbbreviations: Str, streptomycin; Chl, chloramphenicol; Amp, ampicillin; Kan, kanamycin; Tet, tetracycline; ONT, O polysaccharide not typified; HNT, flagellar H antigen
not typified; NM, not motile.
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conditions, the cultures were diluted 1:25 in Penassay broth antibiotic medium 3 (5 g/liter peptone, 1.5
g/liter yeast extract, 1.5 g/liter beef extract, 1 g/liter dextrose, 5 g/liter NaCl, 3.68 g/liter K2HPO4, and 1.32
g/liter KH2PO4) and incubated for 24 h under the same conditions. Finally, the cultures were centrifuged
at 10,000  g for 10 min, and the resulting supernatants were filtered using an 0.2-m membrane.
Anti-Stx2B VHHs. Stx2B-specific VHHs were previously selected by competitive panning using the
immobilized antigen BLS-Stx2B and soluble BLS as a competitor protein from phage display libraries
generated using the BLS-Stx2B chimera as the immunogen (33). Thirteen clones with Stx2-binding
capacity, which included 10 clones belonging to family 1 and one member each belonging to families
2, 6, and 7, were further evaluated by direct ELISA. To assess the interaction of VHHs with Stx2B,
high-binding flat-bottom 96-well plates (Invitrogen) were coated with purified BLS-Stx2B, BLS, GST-Stx2B,
or GST and incubated for 1 h at room temperature with periplasmic extracts (PE) enriched in the
corresponding hemagglutinin (HA)-tagged VHH (HA-VHH). Horseradish peroxidase (HRP)-conjugated
anti-HA antibodies (Roche) were used for detection. The absorbance was read at 450 nm.
Expression and purification of selected VHHs. Selected VHHs were subcloned into the pHEN6
expression plasmid and introduced into the strain E. coli WK6. The resulting strains were grown in Terrific
Broth (2.3 g/liter KH2PO4, 12.5 g/liter K2HPO4, 12 g/liter tryptone, 24 g/liter yeast extract, 4 ml/liter
glycerol) supplemented with 100 g/ml ampicillin and incubated at 37°C with agitation (OD600 of 0.6
to 0.9). The expression of VHHs was induced by adding 1 mM IPTG and incubating the mixture for 18 h
at 28°C with agitation. Periplasmic fractions were obtained by the osmotic shock method (see below),
and the purification was performed by metal-chelate affinity chromatography. Purified VHHs were
dialyzed against phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM
KH2PO4), concentrated, and quantified by the Bradford method according to the manufacturer’s instruc-
tions (Bio-Rad).
Preparation of periplasmic fractions for VHH purification: osmotic shock method. After induc-
tion of the expression of the corresponding VHH, the culture (600 ml) was centrifuged at 10,000  g for
10 min. The resulting pellet was resuspended in TES buffer (200 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, and
0.5 M sucrose) at a concentration factor of 100. After incubation for 1 h at 4°C with orbital agitation, 9 ml
of TES/4 (TES diluted four times in water) was added, and the resulting suspension was incubated for 1
h at 4°C and centrifuged at 10,000  g for 30 min at 4°C, producing the periplasmic fraction in the
supernatant.
Formatting of HA-2vb10 VHH. HA-2vb10 VHH was engineered and expressed as an HA-2vb10-
6His fusion protein. HA-2vb10-6His was generated by fusion of a six-histidine tag at the carboxyl-
terminal end. Nucleotide sequence was obtained from GenScript (GenScript Biotech), and the resulting
molecule was cloned into pHEN6 expression vector. HA-2vb10-6His VHH was expressed and purified as
indicated above.
VHH biotinylation. Purified 2vb10-6His VHH was biotinylated using the EZ-Link sulfo-NHS-LC-
biotinylation kit according to the manufacturer’s instructions (Thermo Fisher Scientific).
HA–anti-HA VHH-based capture ELISA. For the development of the Stx capture ELISA with
detection based on the HA–anti-HA system (HA–anti-HA capture ELISA), 96-well high-binding polysty-
rene microplates (Corning Inc.) were coated with purified VHHs at a concentration of 10 g/ml in 50 mM
carbonate-bicarbonate buffer (pH 9.6) and incubated for 18 h at 4°C. Blocking (2% bovine serum albumin
[BSA], 20 mM Tris-HCl [pH 7.6], 150 mM NaCl, and 0.1% Tween 20) was performed by incubation for 1 h
at room temperature. The recombinant proteins (BLS-Stx2B, GST-Stx2B, BLS, and GST) and the culture
supernatants of the Stx-producing strains were diluted in blocking solution and incubated for 1 h at
room temperature with agitation. HA-tag detection VHHs, obtained from the periplasmic extracts (PE),
were diluted 1:16 in 20% blocking solution in TBS-T (200 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1%
Tween 20) and incubated for 1 h at room temperature with agitation. HA-tag VHHs were detected using
anti-HA antibodies conjugated to horseradish peroxidase (HRP; Roche) diluted in 20% blocking solution
in TBS-T and incubated for 1 h at room temperature with agitation. Between each reaction step, the
plates were washed three times with TBS-T. After incubation with the substrate (0.015% H2O2, 0.1%
3,3=,5,5=-tetramethylbenzidine [TMB] in 0.1 M citrate phosphate buffer, pH 5.0) for 5 min at room
temperature, the reaction was stopped with 0.16 N H2SO4, and the absorbance was measured at 450 nm
(A450) using a microplate reader (DTX 880 multimode detector; Beckman Coulter, Inc.).
Biotin-streptavidin VHH-based capture ELISA. For the development of the Stx capture ELISA with
detection based on the biotin-streptavidin system (biotin-streptavidin capture ELISA), 96-well high-
binding polystyrene microplates (Corning) were coated with purified 1vb1-6His VHH at a concentration
of 2.5 g/ml in 50 mM carbonate-bicarbonate buffer (pH 9.6) and incubated for 18 h at 4°C. The detection
VHH, biotinylated 2vb10-6His VHH (0.8 mg/ml), was diluted 1:16,000 in 50% blocking solution in TBS-T
and detected with streptavidin conjugated to HRP (Thermo Fisher). All other steps were performed as
indicated for the HA–anti-HA capture ELISA.
Other assays. (i) Vero cell cytotoxicity assay. The Vero cell cytotoxicity assay was performed
according to the method of Karmali et al. (15). Briefly, the cells were incubated with the culture
supernatants for 48 h at 37°C. Then, the cells were washed with PBS and incubated for 15 min at room
temperature with the staining solution (0.75% crystal violet, 40% methanol). The cytotoxic activity was
evaluated by observing the staining of the cells with the dye.
(ii) MTT viability assay. The MTT viability assay was performed according to the protocol described
by Mosmann (40). The MTT assay is a quantitative and colorimetric assay based on the ability of living
cells to reduce 4,5-dimethylthiazole-2,5-diphenyltetrazolium (MTT) bromide (Sigma-Aldrich) to formazan
in a reaction catalyzed by mitochondrial dehydrogenases. Vero cell monolayers were grown as indicated
in the Vero cell cytotoxicity assay and incubated for 48 h at 37°C with different dilutions of the culture
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supernatants obtained from the indicated strains. Then, the cells were washed with Earle’s solution
(110 mM NaCl, 54 mM KCl, 1 mM NaH2PO4·H2O, and 5.5 mM glucose), and MTT (stock solution; 5 mg/ml
in PBS) was added to each well at a final concentration of 0.5 mg/ml in cell culture medium without
serum. After incubation for 1.5 h at 37°C, the solution was removed, and the formazan produced by living
cells was solubilized in 200 l of dimethyl sulfoxide (DMSO). The absorbance measured at 655 nm,
corresponding to the substrate not converted to formazan, was subtracted from the absorbance of
formazan measured at 570 nm.
(iii) Commercial ELISA (R-Biopharm). Ridascreen Verotoxin is an enzyme immunoassay for the
qualitative detection of Stx1 and Stx2 that uses specific monoclonal antibodies to Stx1 and Stx2 in a
sandwich-type method (16). The assay was performed according to the manufacturer’s instructions.
(iv) Commercial membrane-based rapid immunoassay (Alere-Abbot). The Shiga Toxin Quik Chek
test is a rapid membrane enzyme immunoassay for the simultaneous qualitative detection and differ-
entiation of Stx1 and Stx2 in a single test device (19–21). This test utilizes specific antibodies against Stx1
and Stx2 and contains a reaction window with three vertical lines of immobilized antibodies. The test
lines “1” and “2” contain monoclonal antibodies against Stx1 and Stx2, respectively, and the control line
“C” is a dotted line that contains anti-HRP antibodies. The conjugate consists of antibodies toward Stx1
and Stx2 coupled to HRP. The assay was performed according to the manufacturer’s instructions.
Stool samples. The samples were obtained from patients under 6 years old with a clinical diagnosis
of diarrhea, bloody diarrhea, or HUS associated or not with STEC infection. The stool samples were
cultured in Gram-negative bacterial broth (GN; 20 g/liter peptone, 1 g/liter dextrose, 2 g/liter D-mannitol,
5 g/liter sodium citrate, 0.5 g/liter sodium deoxycholate, 4 g/liter K2HPO4, 1.5 g/liter KH2PO4, and 5 g/liter
NaCl) for 18 h at 37°C, and the following tests were carried out: (i) FFStx detection by Vero cell
cytotoxicity test, (ii) PCR for stx1/stx2/rfbO157 (41), (iii) PCR for stx1 and stx2 allelic variants as described by
Scheutz et al. (42), (iv) Shiga Toxin Quik Chek membrane-based rapid immunoassay, and (v) VHH-based
Stx2 capture ELISA.
Ethics statement. All the stool samples analyzed in this study were selected from a previously
characterized collection provided by the Servicio Fisiopatogenia, Instituto Nacional de Enfermedades
Infecciosas (INEI)-ANLIS Dr. Carlos G. Malbrán (Argentina), the National Reference Laboratory (NRL) for
HUS and diarrheal diseases associated with diarrheagenic E. coli. These samples were submitted to the
NRL during the 2017–2018 period in the framework of the national surveillance protocol. To ensure
anonymity, the samples were coded upon collection; therefore, no personal identification data of the
patients were available during the study.
RESULTS
Selection of Stx2B-recognizing VHHs and development of a capture ELISA. In a
previous work, VHH phage display libraries were generated using the BLS-Stx2B fusion
protein as an immunogen. Stx2B-specific VHHs were selected by competitive panning
of the phage libraries using the immobilized antigen BLS-Stx2B and soluble BLS as a
competitor protein (33).
In order to select VHHs for the development of an Stx2 capture ELISA, 17 anti-Stx2
VHHs were evaluated by direct ELISA, coating the microplates with BLS-Stx2B, BLS,
GST-Stx2B, and GST. A total of 13 VHHs were selected based on their capacity to
recognize the recombinant B subunit of Stx2 fused to BLS (BLS-Stx2B) and GST
(GST-Stx2B) but not the carrier proteins (see Fig. S1 in the supplemental material).
Previously, anti-Stx2 VHHs were classified into families based on amino acid composi-
tion and length of the CDR3 (33). VHHs selected in this work come from four different
families: 10 VHHs (1vb1, 1vb19, 1vb20, 2vb1, 2vb7, vb8, 2vb10, 2vb11, 2vb21, and
2vb28) belong to family 1 and the remaining three (2vb23, 2vb20, and 2vb6) belong to
families 2, 6, and 7, respectively (Fig. S2).
To select the best capture-detection VHH pair for the development of the capture
ELISA, 10 VHHs fused to histidine tags and purified by metal-chelate affinity chroma-
tography (2vb7, 2vb8, 2vb28, 1vb1, 2vb10, 2vb21, 1vb19, 1vb20, 2vb1, and 2vb11) were
evaluated as capture antibodies. The same 10 plus three additional VHHs (2vb23,
2vb20, and 2vb6) fused to HA and obtained from periplasmic extracts (PE) enriched in
the corresponding VHH were used as detection antibodies (Fig. 1A, HA–anti-HA capture
ELISA). A total of 130 pairwise combinations were evaluated for the detection of
BLS-Stx2B and GST-Stx2B (Fig. 2). Based on this analysis and the expression and
purification yield of the corresponding VHHs, six capture-detection pairs were prelim-
inarily selected (2vb21-2vb10, 1vb1-2vb10, 2vb21-2vb1, 2vb11-2vb1, 2vb11-2vb8, and
1vb1-2vb8). The analytical sensitivity of these pair combinations for the recombinant
proteins BLS-Stx2B and GST-Stx2B was further evaluated (Fig. S3); all VHH pairs except
2vb21-2vb1 were able to detect at least 1.5 ng/well (30 ng/ml) of BLS-Stx2B. 1vb1-
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2vb10 and 2vb21-2vb10 were the VHH pairs with better performance for GST-Stx2B
detection.
In order to determine if the six selected VHH pairs were capable of recognizing
native Stx2 and its variants, and considering that Stx2 is secreted into the culture
medium by producing bacteria (43), culture supernatants from different STEC strains
were obtained as toxin sources and analyzed by the HA–anti-HA capture ELISA.
Bacterial culture supernatants were obtained as described by Karmali et al. with minor
modifications, and Stx release was evaluated by the Vero cell cytotoxicity assay (39) (Fig.
S4). As sources of Stx2a, the prototype variant of Stx2, the reference strains EDL933
(1a/2a) and 02/02 (2a) were used; strains 379/10 (2b), 550/10 (2c), 862/10 (2c), 713/09
(2d), and GG7 (2f) were used as sources of the other Stx2 variants (Table 1). Strain
1091/10, which does not produce Stx2 or Stx1, was used as a negative control. No VHH
pair showed reactivity with the culture supernatants obtained from strains 817/12 and
447/11 (Table 1) used as sources of Stx1a and Stx1c, respectively (data not shown). As
shown in Fig. 3, the VHH pairs 2vb11-2vb1 and 2vb21-2vb1 were not able to detect or
only poorly detected Stx2a; in contrast, the remaining pairs (1vb1-2vb10, 2vb21-2vb10,
2vb11-2vb10, and 2vb11-2vb8) showed high levels of reactivity toward Stx2a (EDL933
and 02/02 strains), which is the Stx2 subtype with the highest clinical and epidemio-
logical relevance. For the other Stx2 variants, only some reactivity against Stx2f (strain
GG7) was observed with 1vb1-2vb10.
Based on these results, the 1vb1-2vb10 VHH pair was selected to continue with the
development and optimization of the capture ELISA for Stx2 detection. To determine
the limit of detection (LOD) of the HA–anti-HA capture ELISA using the 1vb1-2vb10 VHH
pair, different concentrations of the recombinant protein BLS-Stx2B and serial dilutions
of the EDL933 culture supernatant were analyzed (Fig. 4A and B). The LOD for BLS-Stx2B
ranged between 16 ng/ml and 32 ng/ml, and the maximum dilution of STEC culture
supernatant for which native Stx2a could be detected was 1/16.
Optimization and improvement of the capture ELISA. In the assays mentioned
above, detection VHHs were expressed fused to the HA tag and obtained from the
periplasmic extracts (PE) enriched in the corresponding VHH. To be able to purify the
HA-2vb10 VHH used as the detection antibody, it was engineered and expressed as an
HA-2vb10-6His fusion protein (see Materials and Methods). The HA-2vb10-6His was
FIG 1 Schematic representation of the capture ELISAs developed and used in this work for Stx2 detection. (A) VHH-based capture
ELISAs developed in this work for Stx2 detection using specific nanobodies. Purified VHHs fused to a histidine tag (VHH-6His) were
used as capture antibodies. As detection antibodies, three types of VHHs were used: VHHs fused to the HA tag and obtained from the
periplasmic extracts (PE) enriched in the corresponding HA-VHH, a VHH fused to the 6His and HA tags and purified by metal-chelate
affinity chromatography (HA-VHH-6His), and an in vitro biotinylated VHH (biotin-VHH-6His). In the last case, detection was
performed by either spectrophotometry or chemiluminescence. (B) Commercial capture ELISA. This ELISA is based on a pair of
monoclonal antibodies directed to the A subunit of Stx1 and Stx2. TMB, 3,3=,5,5=-tetramethylbenzidine.
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FIG 2 Analysis of 130 VHH capture-detection combinations by the HA–anti-HA capture ELISA. Capture antibodies (VHH-6His) were purified
by metal-chelate affinity chromatography, and detection antibodies (HA-VHHs) were obtained from the periplasmic extracts (PE) enriched in
(Continued on next page)
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purified by metal-chelate affinity chromatography, and the ELISA conditions were
optimized. Using the formatted HA-2vb10-6His VHH and the HA–anti-HA capture
ELISA format (Fig. 1A), high reactivity levels for the recombinant protein BLS-Stx2B were
observed. However, no reactivity for the native Stx2a or the other variants was detected
(Fig. S5). For this reason, and to improve the sensitivity of the capture ELISA, the
purified 2vb10-6His VHH was in vitro biotinylated and a new biotin-streptavidin
capture ELISA was developed and optimized (Fig. 1A, biotin-streptavidin capture ELISA).
FIG 2 Legend (Continued)
the corresponding VHH (Fig. 1A). Each panel corresponds to one capture VHH in combination with each of the 13 detection VHHs. The
recombinant proteins BLS-Stx2B, GST-Stx2B, and BLS (control) were assayed at 1 g/ml (50 ng/well). The arrows indicate the six VHH pairs
selected for further analysis. Reactivity values with GST were similar to those obtained with BLS (data not shown).
FIG 3 Analysis of culture supernatants of the indicated strains by the HA–anti-HA capture ELISA using the six selected VHH pairs. Capture VHHs (VHH-6His)
were purified by metal-chelate affinity chromatography, and detection antibodies (HA-VHHs) were obtained from the periplasmic extracts (PE) enriched in the
corresponding VHH. The recombinant proteins BLS-Stx2B and BLS and also PB (Penassay broth antibiotic medium 3; culture medium used to grow the different
strains) were used as controls. The Shiga toxin type and variant expressed by each strain are indicated in parentheses.
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FIG 4 Detection of recombinant and native Stx2 by the capture ELISAs using the 1vb1-2vb10 VHH capture-detection pair. (A and B) HA–anti-HA capture ELISA
using the 1vb1-6His (purified) and HA-2vb10 VHHs (PE) as capture and detection antibodies, respectively. (C and D) Biotin-streptavidin capture ELISA using
(Continued on next page)
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To determine the detection limit of the biotin-streptavidin capture ELISA, different
concentrations of the recombinant protein BLS-Stx2B and serial dilutions of the EDL933
culture supernatant were analyzed (Fig. 4C and D). The LOD for BLS-Stx2B ranged
between 4 and 8 ng/ml, 4-fold lower than the LOD for the HA–anti-HA capture ELISA.
The maximum dilution of EDL933 culture supernatant for which native Stx2a could be
detected was 1/32 versus 1/16 for the HA–anti-HA capture ELISA. Additionally, in order
to improve the analytical sensitivity of the biotin-streptavidin capture ELISA, the
detection was performed by chemiluminescence instead of spectrophotometry (see
Materials and Methods), but no improvement in the sensitivity of the assay was
observed (Fig. 4E and F).
Taken together, these results demonstrate that the biotin-streptavidin capture ELISA
with spectrophotometric detection is more sensitive than the HA–anti-HA capture
ELISA for the detection of the recombinant as well as the native Stx2a toxins.
Detection of Stx in stool samples. To test the feasibility of the biotin-streptavidin
capture ELISA for the detection of Stx2 in stool, the assay was applied to determine Stx2
in spiked stool samples. For this, a pool of 10 stool samples obtained from patients with
diarrhea not associated with STEC (determined by stool culture, FFStx, and/or stx
detection by PCR) was spiked with different amounts of culture supernatants obtained
from the EDL933, 02/02, or 1091/10 strain and analyzed by the biotin-streptavidin
capture ELISA with spectrophotometric detection (Fig. 5A). The obtained results indi-
cate that the stool matrix does not interfere with Stx2a detection and does not affect
the sensitivity of the capture ELISA; the maximum dilution of STEC culture supernatant
in which the native Stx2a could be detected was 1/32 (Fig. 5A), similar to the one
obtained when diluting the samples in the sample diluent (Fig. 4D). The same spiked
samples were analyzed in parallel with the commercial ELISA kit Ridascreen Verotoxin
(see Materials and Methods). As shown in Fig. 5B, the maximum dilution of EDL933 and
02/02 culture supernatants in which native Stx2a could be detected was 1/8 and 1/2,
respectively, compared to 1/32 and 1/8 for the biotin-streptavidin capture ELISA,
respectively, indicating that the biotin-streptavidin capture ELISA is more sensitive than
the commercial kit for Stx2a detection.
Finally, as a proof of concept, stool samples obtained from patients with diarrhea,
BD, or HUS were analyzed for the presence of Stx2 (Table 2 and Fig. 6). In these samples,
STEC association was confirmed by PCR for stx1 and/or stx2 gene detection from the
confluent growth zone in MacConkey sorbitol agar plates or from the isolated strains.
Based on this analysis, 13 samples were positive for stx2 or stx1 and 9 were negative
(Table 2). By the biotin-streptavidin capture ELISA, high reactivity values were observed
with 9 of 11 stx2-positive samples; as expected, stx1-positive samples (samples 6 and 7)
were negative, and all the stx-negative samples except one (sample 21) showed
negative results (Fig. 6). In parallel, all the samples were also analyzed using the
membrane-based rapid immunoassay Shiga Toxin Quik Chek designed for the detec-
tion of Stx1 and Stx2. The results obtained with the rapid test were similar to those
observed with the VHH-based capture ELISA, except for sample 21, which was negative
by the rapid assay (Table 2). Interestingly, sample 21, obtained from a 2-year-old patient
with clinical diagnosis of HUS, resulted positive for Stx2 by the Vero cell cytotoxicity
assay and the biotin-streptavidin VHH-based capture ELISA developed in this work but
negative for the rest of the laboratory tests, including the PCR techniques (Table 2).
Taken together, these data indicate a high correlation and agreement of the biotin-
streptavidin capture ELISA results with those obtained with stx2 gene detection by PCR
and the commercial kit Shiga Toxin Quik Chek.
FIG 4 Legend (Continued)
the 1vb1-6His (purified) and biotin-2vb10-6His VHHs as capture and detection antibodies, respectively, and spectrophotometric detection. (E and F)
Biotin-streptavidin capture ELISA using the 1vb1-6His (purified) and biotin-2vb10-6His VHHs as capture and detection antibodies, respectively, and
detection by chemiluminescence. The culture supernatants of the indicated strains were evaluated in several dilutions. The Shiga toxin type and variant
expressed by each strain are indicated in parentheses. The 1091/10 strain does not express any Shiga toxin (control).
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Shiga toxins are the distinctive feature and most important virulence factors of STEC
strains irrespective of the E. coli serotype. Therefore, free Stx detection assays and stx
gene detection by PCR are considered the most suitable methods for the early
diagnosis of STEC infections. In addition, timely and accurate diagnosis of STEC infec-
tion is crucial for ensuring proper care of patients as well as avoiding delays in starting
a supportive or, in the case it becomes available, a specific treatment for STEC-HUS. For
these reasons and since VHHs provide many advantages over conventional polyclonal
and monoclonal antibodies or currently used antibody-based fragments, we decided to
exploit VHH single-domain antibodies (nanobodies) derived from camelids to develop
an immunocapture assay for the detection of Stx2.
In the present work, 13 anti-Stx2 VHHs previously obtained from a variable-domain
repertoire library isolated from a llama immunized with the recombinant protein
BLS-Stx2B were selected and evaluated in 130 capture-detection pair combinations for
the detection of the recombinant proteins BLS-Stx2B and GST-Stx2B. Based on this
analysis and the purification yield of the corresponding VHHs, six capture-detection
pairs were selected and further evaluated for their ability to detect the recombinant
proteins and native Stx2 including its variants. In all the VHH capture-detection
combinations, we systematically observed a higher reactivity against BLS-Stx2B than
against GST-Stx2B. This result could be explained by the fact that the llama from which
the library was generated to obtain the VHHs was immunized with the BLS-Stx2B
chimera, and it was previously demonstrated that the BLS scaffold promotes the
FIG 5 Detection of Stx2 in spiked stool samples. A pool of 10 stool samples was spiked with different
amounts of the culture supernatants obtained from the indicated strains. (A) Biotin-streptavidin capture
ELISA with detection by spectrophotometry. (B) Commercial capture ELISA (R-Biopharm). The EDL933
strain expresses Stx1a and Stx2a, 02/02 expresses only Stx2a, and 1091/10 does not express Shiga toxins
(control).
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pentamerization of the toxin, maintaining its Gb3Cer-binding capacity (37). Among the
six VHH capture-detection pairs preliminarily selected, the 1vb1-2vb10 VHH capture-
detection pair displayed the best performance for native Stx2a detection, even showing
some level of reactivity for Stx2f. Therefore, this VHH combination was selected to
develop and optimize a high-performance capture ELISA. To improve the sensitivity of
the assay, the 2vb10-6His detection VHH was purified, in vitro biotinylated, and used
to develop a biotin-streptavidin capture ELISA. This capture ELISA was evaluated using
spectrophotometric and chemiluminescence detection methods, showing a significant
improvement in the LOD for the recombinant and native Stx2a, but no difference in the
performance of the assay was observed between the two detection methods. Addi-
tionally, to test the performance of the VHH-based capture ELISA for Stx2 detection in
stool samples, stools spiked with culture supernatants of Stx2-producing E. coli strains
and fecal samples obtained from patients with diarrhea, bloody diarrhea, or HUS were
evaluated. Stool-spiked experiments showed that the stool matrix does not interfere
with Stx2 detection since the LOD was similar to the one obtained by diluting native Stx2
in sample buffer. Furthermore, the analytical sensitivity was 4-fold higher than that of a
commercial capture ELISA. Finally, the analysis of diarrheal stool samples obtained from
patients demonstrated a high correlation and agreement of the biotin-streptavidin Stx2
capture ELISA results with those obtained with the stx2 detection method by PCR and the
commercial rapid Shiga Toxin Quik Chek immunoassay.
Although anti-Stx VHHs with therapeutic potential have been developed (33, 35),
until now they have not been applied for the development of new Stx detection assays
for the diagnosis of STEC infections. Here, we have demonstrated that VHHs could be
used as new valuable tailor-made diagnostic tools for the detection of Stx in both STEC
culture supernatants and stool samples. The double VHH-based biotin-streptavidin














1 HUS 3 mo O145:NM / stx2a ND Pos (Stx2) Pos
2 BD 6 yr O145:NM / stx2a ND Pos (Stx2) Pos
3 BD 13 mo O157:H7 / stx2a/2c ND Pos (Stx2) Pos
4 BD 1 yr O145:NM / stx2a ND Pos (Stx2) Pos
5 HUS 41 mo O59:H19 / stx2a Pos Pos (Stx2) Pos
6 UFS 10 mo O26:H11 / stx1a ND Pos (Stx1) Neg
7 UFS 1 mo ONT:HNT / stx1a ND Neg Neg
8 HUS 20 mo O157:H7 / stx2a/2c ND Pos (Stx2) Pos
9 D 7 yr O121:HNT / stx2a ND Pos (Stx2) Pos
10 D 11 yr O145:NM / stx2a ND Pos (Stx2) Pos
11 D 10 mo O145:NM / stx2a ND Pos (Stx2) Pos
12 HUS 18 mo O145:NM / stx2a Neg Neg Neg
13 HUS 2 yr O157:H7 / stx2a/2c Neg Neg Neg
14 HUS 11 mo O157:H7 / Neg Neg Neg Neg
15 HUS 21 mo ONT:HNT ND Neg Neg Neg Neg
16 HUS 60 mo ONT:HNT ND Neg Neg Neg Neg
17 D 3 yr ONT:HNT ND Neg ND Neg Neg
18 BD 2 yr ONT:HNT ND Neg ND Neg Neg
19 D 2 yr ONT:HNT ND Neg ND Neg Neg
20 BD 11 mo ONT:HNT ND Neg ND Neg Neg
21e HUS 2 yr ONT:HNT ND Neg Pos Neg Pos
22 BD 3 mo ONT:HNT ND Neg ND Neg Neg
aHUS, hemolytic-uremic syndrome; BD, bloody diarrhea; D, diarrhea; UFS, unspecific febrile syndrome.
bSerotype was determined by seroagglutination using specific antisera. ONT, O polysaccharide not typified; HNT, flagellar H antigen not typified; NM, not motile.
ceae, ehxA, and stx gene(s) detection by PCR. ND, not determined.
dFree fecal Shiga toxin (FFStx) detection in stool samples. Pos, positive; Neg, negative; ND, not determined; VHH-based ELISA, biotin-streptavidin VHH-based capture
ELISA with spectrophotometric detection.
eBacterial isolation, negative; immunomagnetic separation for O157, negative; multiple PCR for rfbO157/stx1/stx2, negative; PCR for diarrheagenic Escherichia coli
including enteropathogenic E. coli (eae), enteroaggregative E. coli (aggR), enteroinvasive E. coli (ipaH), and enterotoxigenic E. coli (heat-labile enterotoxin/heat-stable
enterotoxin), negative; Chemlis E. coli O157, O145, and O121 (Chemtest Argentina S.A., detection of specific IgM and IgG antibodies in serum sample), negative.
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capture ELISA showed an excellent performance for the detection of Stx2a subtype, the
variant of greater clinical and epidemiological relevance, and to a lesser extent Stx2f. In
addition, VHHs provide many advantages over conventional polyclonal and monoclo-
nal antibodies and currently used antibody-based fragments. These advantages are
given by the intrinsic properties of VHHs, including their solubility and structural
stability even under denaturing or high-temperature conditions (44). Furthermore, they
can be efficiently engineered, cloned, and expressed with high yields in economical
expression systems, such as bacteria and yeast, and with high batch-to-batch repro-
ducibility, which allows their production on a large scale and in a standardized manner
in a short period (45). In summary, these characteristics may facilitate the development,
production, and standardization of these immunoreagents, resulting in less expensive
and better diagnostics for STEC-HUS that could be easily transferred to clinical practice.
Additionally, we are applying the VHHs selected in this work for the development of a
rapid (10-min) immunochromatographic assay that would improve access to diagnos-
tics, especially for health care units with minimal infrastructure and untrained staff.
Furthermore, the potential of the VHH technology should allow us to easily broaden the
detection spectrum to Stx1 and its variants as well as the other subtypes of Stx2. All
these aspects will further facilitate the translation of our findings to clinical practice.
The domain structure of VHHs consists in four conserved framework regions (FR1 to
FR4) and three hypervariable complementarity-determining regions (CDR1 to CDR3).
FRs maintain the tertiary structure of the paratope, while the CDRs form the hypervari-
able loops that directly interact with the antigen epitope (46). The typically long and
flexible CDR3 of VHHs makes them particularly capable of binding concave and hidden
epitopes (cryptic epitopes, enzyme active sites, etc.) that are not accessible to conven-
tional antibodies (44). However, the six VHHs selected in this work which displayed the
highest performance (2vb21, 2vb10, 1vb1, 2vb1, 2vb11, and 2vb8) belong to the same
VHH family (family 1) and have a CDR3 significantly shorter (7 amino acid residues) than
the CDR3 length (12, 17, and 20 amino acid residues) of the VHHs of the other families
(see Fig. S2 in the supplemental material). Interestingly, these six VHHs belong to the
same family (family 1) of a previously developed VHH (2vb27 VHH) with therapeutic
potential, which showed an excellent in vitro and in vivo Stx2-neutralizing capacity (33).
FIG 6 Analysis of stool samples obtained from patients with diarrhea, bloody diarrhea, or HUS by the
biotin-streptavidin capture ELISA with spectrophotometric detection. The analysis was performed after
enrichment of the samples in Gram-negative broth (Hajna) (see Materials and Methods). The recombi-
nant proteins BLS-Stx2B and GST-Stx2B, the culture supernatants obtained from STEC strains that
produce Stx1a or Stx1c, and the sample diluent were included as controls. A sample was considered
positive when the A450 value was 3 times higher than the value obtained for the sample diluent (A450 
0.18).
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Further work is needed to characterize and understand how these VHHs with a short
CDR3 are able to efficiently interact with the B subunit of Stx2.
In summary, we have developed and optimized a double (capture-detection) VHH-
based biotin-streptavidin capture ELISA with spectrophotometric detection for Stx2
detection. This assay showed an analytical sensitivity higher than a commercial ELISA
and an excellent clinical sensitivity comparable to the one obtained with the PCR-based
stx2 gene detection method and a commercial rapid immunoassay. This excellent
performance coupled with the intrinsic properties of VHHs (high target affinity and
specificity, stability, and ease of expression at high yields in recombinant bacteria)
makes it an attractive tool for Stx detection and could be of great value for STEC-HUS
diagnosis.
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